Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis

被引:6
|
作者
Omerzu, Tomaz [1 ]
Magdic, Jozef [1 ]
Hojs, Radovan [2 ,3 ]
Potocnik, Uros [2 ]
Gorenjak, Mario [2 ]
Fabjan, Tanja Hojs [1 ,2 ]
机构
[1] Univ Med Ctr Maribor, Dept Neurol, Ljubljanska 5, Maribor 2000, Slovenia
[2] Univ Maribor, Fac Med, Taborska Ulica 8, Maribor 2000, Slovenia
[3] Univ Med Ctr Maribor, Dept Nephrol, Clin Internal Med, Ljubljanska 5, Maribor 2000, Slovenia
关键词
Inflammation; Neuroimmunology; Carotid intima media thickness; Cystatin C; Interleukin  6; CAROTID-ARTERY ATHEROSCLEROSIS; DISABILITY PROGRESSION; FUNCTIONAL COMPOSITE; INFLAMMATION; DISEASE; RISK; COMORBIDITY; DIALYSIS; COMMON;
D O I
10.1007/s00508-021-01862-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Multiple sclerosis is an inflammatory disorder of the central nervous system. Inflammation may create high susceptibility to subclinical atherosclerosis. The purpose of this study was to compare subclinical atherosclerosis and the role of inflammatory cytokines between the group of patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls matched for age and sex. Methods The study group consisted of 112 non-diabetic and non-hypertensive RRMS patients treated with disease modifying drugs (DMD) and the control group was composed of 51 healthy subjects. The common carotid artery (CCA) intima media thickness (IMT) was investigated. Serum levels of risk factors for atherosclerosis and inflammatory cytokines were also determined. Results The mean CCA IMT (0.572 +/- 0.131 mm vs. 0.571 +/- 0.114 mm) did not differ (p > 0.05) between patients and controls. The RRMS patients' CCA IMT was significantly correlated with serum interleukin 6 (IL-6) (p = 0.027), high-sensitivity C-reactive protein (hs-CRP) (p = 0.027), cystatin C (p < 0.0005), glucose (p = 0.031), cholesterol (p = 0.008), LDL (p = 0.021), erythrocyte sedimentation rate (p = 0.001) and triglyceride (p = 0.018) level. We fitted generalized linear models in order to assess the relationship between CCA IMT and IL-6 with adjustment for sex and age. The obtained results showed that adjusted for age (p < 0.001) and sex (p = 0.048) IL-6 serum levels statistically significantly (p = 0.009) predict CCA IMT only in the RRMS group. Conclusion The findings of the present study suggest that when treated with DMD RRMS might not be an independent risk factor for early atherosclerosis presenting with arterial wall thickening; however, the results suggest a significant association of IL-6 serum levels with CCA IMT only in the RRMS group.
引用
收藏
页码:40 / 47
页数:8
相关论文
共 50 条
  • [41] Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study
    Riccio, Paolo
    Rossano, Rocco
    Larocca, Marilena
    Trotta, Vincenzo
    Mennella, Ilario
    Vitaglione, Paola
    Ettorre, Michele
    Graverini, Antonio
    De Santis, Alessandro
    Di Monte, Elisabetta
    Coniglio, Maria Gabriella
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2016, 241 (06) : 620 - 635
  • [42] Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing-remitting multiple sclerosis
    Greco, A
    Minghetti, L
    Puopolo, M
    Cannoni, S
    Romano, S
    Pozzilli, C
    Levi, G
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2004, 224 (1-2) : 23 - 27
  • [43] Severe Disability in Patients with Relapsing-Remitting Multiple Sclerosis Is Associated with Profound Changes in the Regulation of Leptin Secretion
    Rotondi, Mario
    Batocchi, Anna Paola
    Coperchini, Francesca
    Caggiula, Marcella
    Zerbini, Francesca
    Sideri, Riccardo
    Leporati, Paola
    Nociti, Viviana
    Frisullo, Giovanni
    Mirabella, Massimiliano
    Magri, Flavia
    Oliviero, Antonio
    Chiovato, Luca
    NEUROIMMUNOMODULATION, 2013, 20 (06) : 341 - 347
  • [44] Folate receptor alpha autoantibodies in the serum of patients with relapsing-remitting multiple sclerosis (RRMS)
    Mashayekhi, Farhad
    Hadipour, Elham
    Shabani, Somayeh
    Salehi, Zivar
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2024, 237
  • [45] Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis
    Langdon, Dawn W.
    Tomic, Davorka
    Penner, Iris-Katharina
    Calabrese, Pasquale
    Cutter, Gary
    Haering, Dieter A.
    Dahlke, Frank
    Kappos, Ludwig
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (12) : 4135 - 4145
  • [46] Cholesterol level correlate with disability score in patients with relapsing-remitting form of multiple sclerosis
    Durfinova, M.
    Prochazkova, E.
    Petrlenicova, D.
    Bystricka, Z.
    Oresanska, K.
    Kuracka, E.
    Liska, B.
    NEUROSCIENCE LETTERS, 2018, 687 : 304 - 307
  • [47] Secretory Phospholipase A2 activity in serum and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis
    Siroos, Bahaadin
    Balood, Mohammad
    Zahednasab, Hamid
    Mesbah-Namin, Seyed Alireza
    Pourgholy, Fatemeh
    Harirchian, Mohammad Hossein
    JOURNAL OF NEUROIMMUNOLOGY, 2013, 262 (1-2) : 125 - 127
  • [48] Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis
    Foley, John F.
    Barnes, Christopher J.
    Nair, Kavita V.
    JOURNAL OF MANAGED CARE PHARMACY, 2013, 19 (01): : S16 - S23
  • [49] Gut Microbiota as a Potential Predictive Biomarker in Relapsing-Remitting Multiple Sclerosis
    Navarro-Lopez, Vicente
    Mendez-Miralles, Maria Angeles
    Vela-Yebra, Rosa
    Fries-Ramos, Ana
    Sanchez-Pellicer, Pedro
    Ruzafa-Costas, Beatriz
    Nunez-Delegido, Eva
    Gomez-Gomez, Humberto
    Chumillas-Lidon, Sara
    Pico-Monllor, Jose A.
    Navarro-Moratalla, Laura
    GENES, 2022, 13 (05)
  • [50] Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review
    Giovannoni, Gavin
    Mathews, Joela
    NEUROLOGY AND THERAPY, 2022, 11 (02) : 571 - 595